Serological assay for the detection of zika virus-specific antibodies utilizing overlapping peptides comprising an NS2B epitope
AssigneeThe Trustees of Columbia University in the City of New York
InventorsWalter Ian Lipkin, Nischay Mishra, Thomas Briese, Adrian Caciula
Life of this patent
Estimating the term…
Abstract
The current invention provides compositions, methods, and kits for detecting the exposure to and infection by certain viruses. Specifically, the current invention allows for the rapid differential serological detection of exposure to, and infection by viruses. In particular, the current invention allows for the rapid serological detection of exposure to, and infection by Zika virus (ZIKV).
Claims20
A method for the serological detection of an antibody to Zika virus in a sample, comprising:
- a. contacting the sample with a collection of isolated non-redundant peptides specific for antibodies to Zika virus, wherein the peptides are 5 amino acids to 20 amino acids in length of the sequences set forth in SEQ ID NO:
- 1 or SEQ ID NOS:14-22, under conditions sufficient to allow the binding of the antibody(ies) to the peptide(s);
- b. washing antibodies that have not bound to the isolated non-redundant peptides;
- c. labeling bound antibodies with a detectable label;
- and
- d. detecting formation of an antibody-peptide complex comprising said one or more peptides in the collection,
- wherein formation of the complex is indicative of an antibody to an epitope of a Zika antigen being present in the sample.
A method for the serological detection of an antibody to Zika virus in a sample, comprising:
- a. contacting the sample with a collection of isolated non-redundant peptides specific for antibodies to Zika virus, wherein the peptides are 5 amino acids to 20 amino acids in length of the sequences set forth in SEQ ID NOs:
- 2-13 and over 50% reactive in Zika virus convalescent serum samples, under conditions sufficient to allow the binding of the antibody(ies) to the peptide(s);
- b. washing antibodies that have not bound to the isolated non-redundant peptides;
- c. labeling bound antibodies with a detectable label;
- and
- d. detecting formation of an antibody-peptide complex comprising said one or more peptides in the collection,
- wherein formation of the complex is indicative of an antibody to an epitope of a Zika antigen being present in the sample.
Dependencies are inferred from the claim text.